Cancer Treatment

Feb 19, 2025

Peptide drug conjugates (PDCs) represent a groundbreaking approach in targeted therapy, offering a powerful strategy for treating diseases, particularly cancer. Peptide drug conjugates are a class of biopharmaceuticals that combine a therapeutic peptide with a cytotoxic or biologically active drug. The peptide serv...

Nov 22, 2024

NK cell therapies have demonstrated significant clinical efficacy, with studies reporting response rates ranging from 40% to 80% in certain hematologic malignancies. As of recent data, several NK cell therapy candidates are in clinical trials, with notable successes including improved overall survival rates and red...

Mar 29, 2024

In the realm of cancer treatment, the development of targeted therapies has been nothing short of revolutionary. Among these advancements, EGFR inhibitors have emerged as a powerful weapon in the fight against certain types of cancer. EGFR, or Epidermal Growth Factor Receptor, is a protein found on the surface of c...

Mar 15, 2024

Trophoblast cell surface antigen-2 (TROP-2) is a 35-kDa protein found on cell membranes, made of sugars and a protein chain, serving as a transmitter of calcium signals. It is produced by the TACSTD2 gene and shares a structural similarity with the epithelial cell adhesion molecule (EpCAM). TROP2, although ident...

Jan 01, 2024

T-cell receptor (TCR)-dependent treatment involves modified immune cells aimed at attacking particular tumor indicators. This treatment approach necessitates a systematic procedure including patient evaluation (e.g., for HLA-A*02:01 and precise tumor markers), collecting immune cells, creating the altered TCR produ...

Dec 29, 2023

Hematopoietic progenitor kinase (HPK1) belongs to the family of Ste20 serine/threonine kinases known as mitogen-activated protein kinase kinase kinase kinase (MAP4K). It is primarily expressed in hematopoietic cells and functions as a negative regulator of T-cell receptor (TCR) and B-cell signaling, serving as an i...

Dec 15, 2023

Date of Abstract presentation11th December 2023IndicationsAggressive B-cell lymphoma (a-BCL)Abstract Number4459Abstract typePoster Approximately 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) experience relapse following initial treatment with rituximab, cyclophosphamide, doxorubicin, vincr...

Dec 15, 2023

Date of Abstract presentation9th December 2023IndicationsRelapsed/Refractory (r/r) Large B-Cell and Follicular LymphomasAbstract Number2095Abstract typePoster Despite the rising clinical fascination with autologous CAR T-cell therapies for hematologic malignancies and their noteworthy achievements, persistent ch...

Dec 15, 2023

Date of Abstract presentation11th December 2023IndicationsDiffuse large B-cell lymphoma (DLBCL)Abstract Number4496Abstract typePoster Diffuse large B-cell lymphoma (DLBCL) stands as a swiftly progressing and aggressive ailment, representing the predominant type of non-Hodgkin lymphoma (NHL) and encompassing one-...

Dec 15, 2023

Date of Abstract presentation11th December 2023IndicationsFollicular LymphomaAbstract Number984Abstract typeOral ZYNLONTA stands as an innovative CD19-directed antibody-drug conjugate (ADC). Upon binding to a cell expressing CD19, ZYNLONTA undergoes internalization, releasing a pyrrolobenzodiazepine (PBD) payloa...